Post-marketing safety monitoring of Shenqifuzheng injection: A solution made of Dangshen (Radix Codonopsis) and Huangqi (Radix Astragali Mongolici)

Journal of Traditional Chinese Medicine

Volumn 34, Issue 4, 2014, Pages 498-503

  Ai, Qinghua ^a   Zhang, Wen ^a   Xie, Yanming ^a   Huang, Wenhua ^b   Liang, Hong ^b   Cao, Hui ^c  

^a INSTITUTE OF CHINESE MATERIA MEDICA   (China)

^b Livzon (Group) Limin Pharmaceutical Factory   (China)

^c National Engineering Research Center for Modernization of TCM Livzon (Group) Limin Pharmaceutical Factory   (China)

Author keywords

Post marketing re evaluation; Safety research; Shenqifuzheng injection

Indexed keywords

ANTIDIABETIC AGENT; CARDIOVASCULAR AGENT; PLANT EXTRACT; SHENQIFUZHENG INJECTION; UNCLASSIFIED DRUG; HERBACEOUS AGENT;

ACUTE TOXICITY; ADJUVANT THERAPY; ANTIDIABETIC ACTIVITY; ASTRAGALUS PLANT; CHINESE MEDICINE; CODONOPSIS PILOSULA; DOMESTIC RABBIT; DRUG EFFICACY; DRUG MARKETING; DRUG MONITORING; DRUG SAFETY; EXPERIMENTAL DOG; GOOD LABORATORY PRACTICE; KIDNEY FUNCTION; LIVER FUNCTION; NONHUMAN; PHASE 4 CLINICAL TRIAL (TOPIC); RADIX ASTRAGALI MONGOLICI; REVIEW; SYSTEMATIC REVIEW; TREATMENT DURATION; ADVERSE DRUG REACTION; ANIMAL; ANIMAL MODEL; CHEMISTRY; CHINA; CODONOPSIS; ECONOMICS; HUMAN; POSTMARKETING SURVEILLANCE;

ANIMALS; ASTRAGALUS PLANT; CHINA; CODONOPSIS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; DRUGS, CHINESE HERBAL; HUMANS; MODELS, ANIMAL; PRODUCT SURVEILLANCE, POSTMARKETING;

EID: 84907396760     PISSN: 02552922     EISSN: 2589451X     Source Type: Journal    
DOI: 10.1016/s0254-6272(15)30053-4     Document Type: Review

References (8)

1. Song CS. Study on general pharmacology experimental material and documents of Shenqi injiection. Dongzhimen hospital of Beijing University of Chinese Medicine, 1987.
2. Xie YM, Tian F. A discussion of key issues on postmarketing reevaluation of Chinese medicine. Zhong Guo Zhong Yao Za Zhi 2010; 35(11): 1494-1497.
3. Xie YM. WEI Design requirements for clinical trails on re-evaluation of safety and efficacy of post-marketed Chinese herbs. Zhong Guo Zhong Yao Za Zhi 2011; 36(20): 2768-2770.
4. Li YY, Zhao M, Xie YM, Li L, You L. Analysis of clinical of parenterally administered Shenqi Fuzheng on renal function. Zhong Guo Zhong Yao Za Zhi 2013; 38(18): 3031-3038.
5. Ai QH, Zeng XB, Xie YM. The effects of parenterally administered Shenqifuzheng on patient outcomes with tumor using propensity score. Zhong Guo Zhong Yao Za Zhi 2013; 38(18): 3129-3136.
6. Shen H, Ai QH, Xie YM, et al. Parenterally administered Shenqifuzheng for heart failure: a systematic review and Meta-analysis. Zhong Guo Zhong Yao Za Zhi 2013; 38 (18): 3200-3208.
7. Zhang S, Zhang L, Shang HC. System evaluation of synergy and attenuation effects of Shenqifuzheng injection for cancer. Zhong Guo Zhi Ye Yao Shi 2012; 19(12): 17.
8. Xu HB. Li System evaluation of adjuvant chemotherapy effects of Shenqifuzheng injection for cancer. Zhong Guo Yao Xue Za Zhi 2010; 45(22): 1767.